日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patients

染色体着丝粒拷贝数扩增与HER2阳性转移性乳腺癌患者的卓越疗效相关

期刊:Oncogene
影响因子:7.3
doi:10.1038/s41388-025-03667-8
Andrieu, Charlotte; Stoof, Jojanneke; AlSultan, Dalal; Ivers, Laura; Berenguer Pina, Jose Javier; Skrobo, Darko; Ballot, Jo; O'Reilly, Debbie; Collins, Denis M; Eustace, Alex J; Quinn, Cecily; Walshe, Janice M; Gullo, Giuseppe; Walsh, Naomi; Crown, John
HER2
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Physiologically-Based Pharmacokinetics of Ribociclib Drug-Drug Interactions and Organ Impairment Pharmacokinetics in Early Breast Cancer

基于生理的瑞博西尼药代动力学：药物相互作用及早期乳腺癌器官损害药代动力学

期刊:Pharmaceuticals
影响因子:4.8
doi:10.3390/ph19030461
Ji, Yan; Huth, Felix; Wang, Craig; Schiller, Hilmar; Combes, Francois Pierre; Crown, John; Fasching, Peter A; Zarate, Juan Pablo; Untch, Michael
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Cis-regulatory and long noncoding RNA alterations in breast cancer - current insights, biomarker utility, and the critical need for functional validation

乳腺癌中的顺式调控和长链非编码RNA改变——当前认识、生物标志物应用以及功能验证的迫切需求

期刊:Molecular Oncology
影响因子:4.5
doi:10.1002/1878-0261.70157
Cuy Saqués, Arnau; Martinez-Mendez, Aracele; Crown, John; Eustace, Alex
信号转导
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Correction: miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer

更正：miR-630靶向IGF1R，调节HER2过表达乳腺癌中对HER靶向药物的反应和癌细胞的整体进展。

期刊:Molecular Cancer
影响因子:33.9
doi:10.1186/s12943-025-02251-8
Corcoran, Claire; Rani, Sweta; Breslin, Susan; Gogarty, Martina; Ghobrial, Irene M; Crown, John; O'Driscoll, Lorraine
肿瘤
HER2
肿瘤免疫
IGF1
乳腺癌
细胞生物学
发表日期：2025
文献求助 收藏

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial

瑞博西尼联合内分泌治疗激素受体阳性/ERBB2阴性早期乳腺癌：NATALEE随机临床试验的4年结果

期刊:Jama Oncology
影响因子:20.1
doi:10.1001/jamaoncol.2025.3700
Fasching, Peter A; Stroyakovskiy, Daniil; Yardley, Denise A; Huang, Chiun-Sheng; Crown, John; Bardia, Aditya; Chia, Stephen; Im, Seock-Ah; Martin, Miguel; Xu, Binghe; Loi, Sherene; Barrios, Carlos; Untch, Michael; Moroose, Rebecca; Visco, Frances; Hortobagyi, Gabriel N; Slamon, Dennis J; Fresco, Rodrigo; Zarate, Juan Pablo; Li, Zheng; Waters, Sorcha; Hurvitz, Sara A
肿瘤
肿瘤免疫
ERBB2
信号转导
乳腺癌
免疫/内分泌
发表日期：2025
文献求助 收藏

Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer.

Amcenestrant联合疗法治疗HER2+/ER+乳腺癌的临床前理论依据

期刊:International Journal of Molecular Sciences
影响因子:4.9
doi:10.3390/ijms26020460
Mahdi Amira F, Ashfield Niall, Crown John, Collins Denis M
肿瘤
乳腺癌
发表日期：2025
文献求助 收藏

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

体重指数作为早期乳腺癌患者辅助紫杉烷类化疗疗效的预测因素：来自GEICAM西班牙乳腺癌研究组和TRIO肿瘤转化研究组的辅助治疗研究汇总分析

期刊:International Journal of Cancer
影响因子:4.7
doi:10.1002/ijc.35432
García-Saenz, José A; Spera, Gonzalo; Pollán, Marina; Bermejo, Begoña; Ruiz-Borrego, Manuel; Chan, Arlene; Martín, Miguel; Guerrero-Zotano, Ángel; Calvo, Lourdes; Rodríguez-Lescure, Álvaro; Marín, María; Chap, Linnea; Crown, John; Pienkowski, Tadeusz; Bee, Valerie; Casas, Maribel; Polonio, Óscar; Bezares, Susana; Slamon, Dennis
TRIO
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials

乳腺癌辅助化疗试验中，中期终点可作为长期疗效的替代指标

期刊:Oncologist
影响因子:4.2
doi:10.1093/oncolo/oyaf263
Blasco, Andrea; López-Tarruella, Sara; Urruticoechea, Ander; Carrasco, Eva; Spera, Gonzalo; Martín, Miguel; Bermejo, Begoña; Chap, Linnea; Ruiz-Borrego, Manuel; Crown, John; García-Saenz, Jose A; Chan, Arlene; Guerrero-Zotano, Ángel; Semiglazov, Vladimir; Calvo, Lourdes; Pienkowski, Tadeusz; Herranz, Jesús; Slamon, Dennis
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

MYC as a Target for Cancer Treatment: from Undruggable to Druggable?

MYC作为癌症治疗靶点：从不可成药到可成药？

期刊:Targeted Oncology
影响因子:4
doi:10.1007/s11523-025-01169-x
Duffy, Michael J; Tang, Minhong; Crown, John
MYC
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis

TCHL——一项评估TCH（多西他赛、卡铂和曲妥珠单抗）和TCHL（多西他赛、卡铂、曲妥珠单抗和拉帕替尼）方案在HER-2阳性乳腺癌患者中疗效的II期新辅助治疗研究：一项为期5年的随访研究及血清生物标志物分析

期刊:Acta Oncologica
影响因子:2.2
doi:10.2340/1651-226X.2025.43143
Crown, John; Eustace, Alex J; Collins, Denis M; Keane, Maccon; Coate, Linda; Kennedy, John; O'Reilly, Seamus; Kelly, Catherine; O'Connor, Miriam; Martin, Michael; Murphy, Conleth; Duffy, Karen; Walshe, Janice; Gullo, Giuseppe; Mahgoub, Thamir; Alvarez-Iglesias, Alberto; Parker, Imelda; Donachie, Vicky; Teiserskiene, Ausra; Madden, Stephen F; Moulton, Brian; O'Donovan, Norma; Hennessy, Bryan T
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏